Compile Data Set for Download or QSAR
maximum 50k data
Report error Found 130 Enz. Inhib. hit(s) with all data for entry = 2715
TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376888(4-(aminomethyl)-1-[2,3-difluoro-5-(3-fluorophenoxy...)
Affinity DataIC50:  0.891nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376885(4-(aminomethyl)-1-[2,5-difluoro-3-(3-fluorophenoxy...)
Affinity DataIC50:  0.912nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376906(6-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidi...)
Affinity DataIC50:  1.26nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376902(3-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluor...)
Affinity DataIC50:  1.38nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376884(4-(aminomethyl)-1-[3-fluoro-5-(3-fluorophenoxy)phe...)
Affinity DataIC50:  1.51nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376872(1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidi...)
Affinity DataIC50:  1.58nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376901((3S or 3R)-3-[(cyclopropylamino)methyl]-1-[4-(3-fl...)
Affinity DataIC50:  1.78nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376881(4-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluor...)
Affinity DataIC50:  1.91nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376900(3-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy...)
Affinity DataIC50:  1.91nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376881(4-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluor...)
Affinity DataIC50:  2.75nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376871(4-[(dimethylamino)methyl]-1-[4-(3-fluorophenoxy)-6...)
Affinity DataIC50:  3.47nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376890(US9920053, Example 20 | {4-amino-1-[4-(3-fluorophe...)
Affinity DataIC50:  4.07nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376875(1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidi...)
Affinity DataIC50:  4.68nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376883(US9920053, Example 13 | {4-fluoro-1-[4-(3-fluoroph...)
Affinity DataIC50:  4.90nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376895(N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyri...)
Affinity DataIC50:  5.01nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376904(N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyri...)
Affinity DataIC50:  5.62nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376899(2-amino-N-({1-[4-(3-fluorophenoxy)-6-(trifluoromet...)
Affinity DataIC50:  6.03nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376887(4-(aminomethyl)-1-[2-fluoro-3-(3-fluorophenoxy)phe...)
Affinity DataIC50:  6.76nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376873(4-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy...)
Affinity DataIC50:  7.41nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376877(4-(1,4-diazepan-1-ylmethyl)-1-[4-(3-fluorophenoxy)...)
Affinity DataIC50:  8.71nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376889(4-(aminomethyl)-1-[3,4-difluoro-5-(3-fluorophenoxy...)
Affinity DataIC50:  9.55nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376879(4-[(tert-butylamino)methyl]-1-[4-(3-fluorophenoxy)...)
Affinity DataIC50:  12.3nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376905(4-(3-fluorophenoxy)-2-{3H,4H,5H,6H,7H-imidazo[4,5-...)
Affinity DataIC50:  12.6nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376898(N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyri...)
Affinity DataIC50:  13.8nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376891(N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyri...)
Affinity DataIC50:  14.5nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376886(4-(aminomethyl)-1-(2-fluoro-3-phenoxyphenyl)piperi...)
Affinity DataIC50:  15.5nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376893(N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyri...)
Affinity DataIC50:  17.8nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376897(N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyri...)
Affinity DataIC50:  19.1nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376878(4-[(2,5-dimethylpyrrolidin-1-yl)methyl]-1-[4-(3-fl...)
Affinity DataIC50:  21.9nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376896(N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyri...)
Affinity DataIC50:  22.4nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376892(2-cyclopropyl-N-({1-[4-(3-fluorophenoxy)-6-(triflu...)
Affinity DataIC50:  26.3nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent noradrenaline transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376872(1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidi...)
Affinity DataIC50:  26.9nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent noradrenaline transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376906(6-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidi...)
Affinity DataIC50:  30.9nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent noradrenaline transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376888(4-(aminomethyl)-1-[2,3-difluoro-5-(3-fluorophenoxy...)
Affinity DataIC50:  30.9nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376894(N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyri...)
Affinity DataIC50:  38nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376874(4-{[cyclopropyl(methyl)amino]methyl}-1-[4-(3-fluor...)
Affinity DataIC50:  41.7nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent noradrenaline transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376885(4-(aminomethyl)-1-[2,5-difluoro-3-(3-fluorophenoxy...)
Affinity DataIC50:  57.5nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376880(1-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyri...)
Affinity DataIC50:  66.1nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent noradrenaline transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376871(4-[(dimethylamino)methyl]-1-[4-(3-fluorophenoxy)-6...)
Affinity DataIC50:  100nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent noradrenaline transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376884(4-(aminomethyl)-1-[3-fluoro-5-(3-fluorophenoxy)phe...)
Affinity DataIC50:  117nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376876(4-[(3,3-difluoropyrrolidin-1-yl)methyl]-1-[4-(3-fl...)
Affinity DataIC50:  129nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent noradrenaline transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376901((3S or 3R)-3-[(cyclopropylamino)methyl]-1-[4-(3-fl...)
Affinity DataIC50:  138nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent noradrenaline transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376881(4-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluor...)
Affinity DataIC50:  145nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetPotassium voltage-gated channel subfamily H member 2(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376878(4-[(2,5-dimethylpyrrolidin-1-yl)methyl]-1-[4-(3-fl...)
Affinity DataIC50:  158nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent noradrenaline transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376900(3-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy...)
Affinity DataIC50:  166nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetPotassium voltage-gated channel subfamily H member 2(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376872(1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidi...)
Affinity DataIC50:  200nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent noradrenaline transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376875(1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidi...)
Affinity DataIC50:  245nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetPotassium voltage-gated channel subfamily H member 2(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376871(4-[(dimethylamino)methyl]-1-[4-(3-fluorophenoxy)-6...)
Affinity DataIC50:  251nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent noradrenaline transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376904(N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyri...)
Affinity DataIC50:  275nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent noradrenaline transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM376877(4-(1,4-diazepan-1-ylmethyl)-1-[4-(3-fluorophenoxy)...)
Affinity DataIC50:  295nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


Displayed 1 to 50 (of 130 total ) | Next | Last >>
Jump to: